Valentina Gambardella

INCLIVA Health Research Institute

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (5)

Josefa Castillo Aliaga

Profesor Ayudante Doctor

University of Valencia

SPAIN

View details

Luis Franco

INCLIVA Health Research Institute

SPAIN

View details

Philippe L. Bedard

University Health Network

CANADA

View details

Sheila Zuniga

Head of

INCLIVA Health Research Institute

SPAIN

View details

Sebastián Blesa

INCLIVA Health Research Institute

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Valentina Gambardella

Research Interests

Explore related searches

Contact this professor

Articles (10)

Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study

Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer

Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review.

Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy.

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.

Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre.

Personalized Medicine: Recent Progress in Cancer Therapy.

Collaborators (5)

Josefa Castillo Aliaga

Luis Franco

Philippe L. Bedard

Sheila Zuniga

Sebastián Blesa

Make your next move.